TransMedics (TMDX) Revenue (2018 - 2026)

TransMedics' Revenue history runs 9 years deep, the most recent figure standing at $173.9 million for Q1 2026.

• On a quarterly basis, Revenue rose 21.18% year-over-year to $173.9 million in Q1 2026; TTM through Mar 2026 was $635.9 million, a 30.24% increase from a year earlier, with the FY2025 full-year figure at $605.5 million, up 37.13% from the prior year.
• Revenue climbed to $173.9 million in Q1 2026 per TMDX's latest filing, from $160.8 million in the prior quarter.
• Across five years, Revenue topped out at $173.9 million in Q1 2026 and bottomed at $15.9 million in Q1 2022.
• The 5-year median for Revenue is $96.8 million (2024), against an average of $91.5 million.
• Across the five-year window, Revenue surged 378.27% in 2022 and grew 21.18% in 2026, its largest moves.
• Year by year, Revenue stood at $31.4 million in 2022, then jumped by 158.72% to $81.2 million in 2023, then soared by 49.83% to $121.6 million in 2024, then jumped by 32.18% to $160.8 million in 2025, then advanced by 8.19% to $173.9 million in 2026.
• Per Business Quant, the three latest TMDX Revenue figures stand at $173.9 million (Q1 2026), $160.8 million (Q4 2025), and $143.8 million (Q3 2025).